NIH

$1.8 Million Fast-Track NIH SBIR Grant for Manocept™ Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to Navidea

Authors:
Steven Giannos
Date:
Business Wire: May 26, 2016 – DUBLIN, OH, U.S.A. – Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced the receipt of an initial notice of award for a fast-track Small Business Innovation Research (SBIR) grant providing for up to $1.8 million from the National Institutes of Health’s (NIH’s…

join_crs.jpg